Overcoming the hurdles to achieving glycemic control.

作者: Kenneth M. Shaw

DOI: 10.1016/J.METABOL.2006.02.001

关键词: GlycemicType 2 diabetesInternal medicineType 2 Diabetes MellitusHypoglycemiaEndocrine diseaseGlimepirideDiabetes mellitusMedicineEndocrinologyGliclazide

摘要: Abstract Several factors influence diabetes control, and many of these can adversely affect endeavors to obtain optimal glycemic management. For patients with type 2 mellitus, the passage time often results in a loss responsiveness medication greater difficulty achieving desired target levels. Although observations part reflect natural progression diabetes, irrespective treatment given, it is possible identify modifiable hurdles that be addressed better outcome results. Lifestyle measures, particularly diet exercise, remain paramount, whereas other secondary confounding such as systemic or endocrine disease conflicting need specific therapeutic attention. Most mellitus will require oral hypoglycemic this should prescribed simplest, most effective, safest way. Ensuring fully understand objectives important resulting compliance advised treatment. Such significantly improved by keeping regimens simple. With its novel once-daily formulation, gliclazide modified release has been shown improve adherence result determined HbA 1c Its benefits terms reduced risk hypoglycemia have demonstrated GlUcose control In diabetes: Diamicron versus glimEpiride study.

参考文章(14)
Robert C Turner, Carole A Cull, Valeria Frighi, Rury R Holman, UK Prospective Diabetes Study (UKPDS) Group, UK Prospective Diabetes Study (UKPDS) Group, None, Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49) JAMA. ,vol. 281, pp. 2005- 2012 ,(1999) , 10.1001/JAMA.281.21.2005
Pierre-Jean Guillausseau, Observance et optimisation du traitement antidiabétique oral: Étude longitudinale Presse Medicale. ,vol. 33, pp. 156- 160 ,(2004) , 10.1016/S0755-4982(04)98512-0
Kiyoko Kimoto, Kenji Suzuki, Takako Kizaki, Yoshiaki Hitomi, Hitoshi Ishida, Hidenori Katsuta, Eisuke Itoh, Tomomi Ookawara, Keiichiro Suzuki, Koichi Honke, Hideki Ohno, Gliclazide protects pancreatic β-cells from damage by hydrogen peroxide Biochemical and Biophysical Research Communications. ,vol. 303, pp. 112- 119 ,(2003) , 10.1016/S0006-291X(03)00310-3
P. H Winocour, Effective diabetes care: a need for realistic targets BMJ. ,vol. 324, pp. 1577- 1580 ,(2002) , 10.1136/BMJ.324.7353.1577
Andrew Harrower, Gliclazide modified release: from once-daily administration to 24-hour blood glucose control. Metabolism-clinical and Experimental. ,vol. 49, pp. 7- 11 ,(2000) , 10.1053/META.2000.17823
Julia Lawton, Naureen Ahmad, Nina Hallowell, Lisa Hanna, Margaret Douglas, Perceptions and experiences of taking oral hypoglycaemic agents among people of Pakistani and Indian origin: qualitative study BMJ. ,vol. 330, pp. 1247- 1250 ,(2005) , 10.1136/BMJ.38460.642789.E0
Jo Satoh, Kazuma Takahashi, Yumiko Takizawa, Hisamitsu Ishihara, Masashi Hirai, Hideki Katagiri, Yoshinori Hinokio, Susumu Suzuki, Ichiro Tsuji, Yoshitomo Oka, Secondary sulfonylurea failure: Comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide Diabetes Research and Clinical Practice. ,vol. 70, pp. 291- 297 ,(2005) , 10.1016/J.DIABRES.2005.04.002